ReviewNanomedicine (London, England)2009
NanoART, neuroAIDS and CNS drug delivery.
Review in Nanomedicine (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed.
- Review
- Recent advances in therapeutic strategies for Alzheimer's and Parkinson's disease using protein/peptide co-modified polymer nanoparticles.Neuroprotection (Chichester, England) · 2024Review
- Formulation and Characterization of Silibinin Entrapped Nano-Liquid Crystals for Activity against AβAAPS PharmSciTech · 2024Article
- Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?Pharmaceutics · 2022Review
- Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND).Current HIV/AIDS reports · 2022Review
- Review
- Innovative Delivery Systems Loaded with Plant Bioactive Ingredients: Formulation Approaches and Applications.Plants (Basel, Switzerland) · 2021Review
- Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles.Pharmaceutics · 2021Article
- Enhanced target cell specificity and uptake of lipid nanoparticles using RNA aptamers and peptides.Beilstein journal of organic chemistry · 2021Article
- Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies.Open biology · 2020Review
- An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles.International journal of pharmaceutics · 2020Article
- Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.Molecular biomedicine · 2020Review
- Nanotechnology approaches to eradicating HIV reservoirs.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019Review
- Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery.Pharmaceutics · 2019Review
- 110Industrial & engineering chemistry research · 2019Article
- Modulating cellular autophagy for controlled antiretroviral drug release.Nanomedicine (London, England) · 2018Article
- Harnessing nanostructured systems for improved treatment and prevention of HIV disease.Bioengineering & translational medicine · 2018Review
- The Role of HIV Infection in Neurologic Injury.Brain sciences · 2017Review
- Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.The Journal of clinical investigation · 2017Article
- Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A broad range of nanomedicines is being developed to improve drug delivery for CNS disorders. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of metabolic enzymes pose hurdles for drug-brain entry. Nanoformulations can circumvent the BBB to improve CNS-directed drug delivery by affecting such pumps and enzymes. Alternatively, they can be optimized to affect their size, shape, and protein and lipid coatings to facilitate drug uptake, release and ingress across the barrier. This is important as the brain is a sanctuary for a broad range of pathogens including HIV-1. Improved drug delivery to the CNS would affect pharmacokinetic and drug biodistribution properties. This article focuses on how nanotechnology can serve to improve the delivery of antiretroviral medicines, termed nanoART, across the BBB and affect the biodistribution and clinical benefit for HIV-1 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.